Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Celartics Biopharma Co. Ltd. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is assigned to 1 distinct examiner, ROGERS, ERIC JASON, who also serves as the busiest examiner for the portfolio. Because the busiest examiner is responsible for 1 pending office action, this individual handles the total pending workload for the company in this sector.
The portfolio is concentrated within 1 distinct art unit. This indicates that the company's current patenting efforts are focused on a specific technical area rather than being spread across different disciplines. For a practitioner, this means that the prosecution strategy can be tailored specifically to the rules and tendencies of this 1 art unit and the 1 distinct examiner involved.
The presence of 1 distinct examiner and 1 distinct art unit for the pending workload suggests a streamlined prosecution environment. The applicant's success in the Biotechnology & Pharmaceuticals field is currently tied to the outcomes of this specific interaction. This structure requires a targeted approach to address the requirements of the individual reviewing the application, as the pending office action represents the total active portfolio in the data.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17050085 | METHOD FOR EXPANDING HUMAN DC CELL AND HUMAN DC CELL RESOURCE LIBRARY | ROGERS, ERIC JASON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17050085 | METHOD FOR EXPANDING HUMAN DC CELL AND HUMAN DC CELL RESOURCE LIBRARY | ROGERS, ERIC JASON | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17050085 | METHOD FOR EXPANDING HUMAN DC CELL AND HUMAN DC CELL RESOURCE LIBRARY | ROGERS, ERIC JASON | 1638 | §103§112 | Non-Final OA | — | Pending | Oct 23, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial